Jaroslaw Maciejewski
Chairman, Department of Translational Hematology and Oncology Research · Case Western Reserve University
Credentials: · · · ·
History
- Present
Department of Translational Hematology and Oncology Research · Case Western Reserve University
- 1999–2000
Lung and Blood Institute
Research
Revised international prognostic scoring system for myelodysplastic syndromes
Blood · 2012 · 2,603 citations
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Nature · 2010 · 1,087 citations
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
New England Journal of Medicine · 2006 · 994 citations
158 papers
- NY
78 papers
- RT
56 papers
48 papers
45 papers · 44 as a resident
- AL
44 papers
44 papers
43 papers
Grants
- 2025–2030
Investigating the Role of VISTA in Driving Immune Evasion in Acute Myeloid Leukemia
National Cancer Institute · R01
PI · $1.3M · Cleveland Clinic Lerner Com-Cwru
- 2026–2030
National Heart, Lung, and Blood Institute · R01
Contact PI · $628K · Cleveland Clinic Lerner Com-Cwru
- 2022–2027
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $3.3M · Cleveland Clinic Lerner Com-Cwru
- 2021–2026
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms
National Cancer Institute · R01
Contact PI · $3M · Cleveland Clinic Lerner Com-Cwru
Clinical trials
- 2005–2010
Principal investigator · Completed · Phase 2
The Cleveland Clinic
- 2006–2009
Identifying Characteristics of Bone Marrow Failure Syndromes
Study chair · Unknown
Office of Rare Diseases (ORD)
- 2007–2010
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Site PI · Unknown · Phase 2
Office of Rare Diseases (ORD)
- 2006–2009
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
Site PI · Unknown · Phase 1, Phase 2
Office of Rare Diseases (ORD)